NCT04192981: GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

NCT04192981
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: PI3K
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: 
Exclusions: Patients with brain metastases eligible for single fraction stereotactic radiation therapy
https://ClinicalTrials.gov/show/NCT04192981

Comments are closed.

Up ↑